1. Advanced preparation of fragment libraries enabled by oligonucleotide-modified 2 ',3 '-dideoxynucleotides
  2. Characteristics of the boards of directors at firms listed on Nasdaq Baltic
  3. Potential of miR-181a-5p and miR-630 as clinical biomarkers in NSCLC